[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019

December 2019 | 83 pages | ID: RD999985A241EN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019'; RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) pipeline Target constitutes close to 13 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes.

RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - RAC-alpha serine/threonine-protein kinase is an enzyme encoded by the AKT1 gene. It regulates many processes including metabolism, proliferation, cell survival, growth and angiogenesis. This is mediated through serine or threonine phosphorylation of a range of downstream substrates. It regulates the storage of glucose in the form of glycogen by phosphorylating GSK3A and GSK3B resulting in inhibition of its kinase activity. It act as key modulator of the AKT-mTOR signaling pathway controlling the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I).

The report 'RAC Alpha SerineThreonine Protein Kinase - Pipeline Review, H2 2019' outlays comprehensive information on the RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 5, 2 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Hematological Disorders, Non Malignant Disorders and Undisclosed which include indications Endometrial Cancer, Hepatocellular Carcinoma, Melanoma, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Triple-Negative Breast Cancer (TNBC), Prostate Cancer, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Solid Tumor, Anal Cancer, Fallopian Tube Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Pancreatic Cancer, Peritoneal Cancer, Proteus Syndrome, Sickle Cell Disease, Small-Cell Lung Cancer, Thymoma (Thymic Epithelial Tumor), Unspecified Rare Disease and Uterine Cancer.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1)
  • The report reviews RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Overview
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Companies Involved in Therapeutics Development
ArQule Inc
AstraZeneca Plc
Bayer AG
Laekna Therapeutics Shanghai Co Ltd
Merck & Co Inc
Merck KGaA
Novartis AG
Rexahn Pharmaceuticals Inc
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Drug Profiles
ARQ-751 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1125976 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
capivasertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-2698 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miransertib mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2206 + selumetinib sulfate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NISC-6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RX-0201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RX-0301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AKT1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trametinib dimethyl sulfoxide + uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
uprosertib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Dormant Products
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Discontinued Products
RAC Alpha Serine/Threonine Protein Kinase (Protein kinase B or Protein kinase B Alpha or Proto Oncogene c Akt or RAC PK Alpha or AKT1 or EC 2.7.11.1) - Product Development Milestones
Featured News & Press Releases
Oct 29, 2019: ArQule presents recent data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 21, 2019: ArQule announces preclinical data demonstrating potential of Miransertib (ARQ 092) to treat PIK3CA-driven vascular malformations at 2019 ASHG Annual Meeting
Oct 16, 2019: ArQule announces presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 08, 2019: ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting
Oct 02, 2019: ArQule announces first patient dosed in registrational MOSIAC trial of Miransertib for the treatment of Proteus Syndrome and PIK3CA-related Overgrowth Spectrum
Jun 17, 2019: ArQule announces preliminary results from its phase 1/2 study of Miransertib (ARQ 092), in Patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation at the European Society of Human Genetics Conference
Jun 10, 2019: ArQule announces oral presentation for its Pan-AKT inhibitor, miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference
Feb 25, 2019: ArQule announces publication of clinical data with Miransertib in Proteus syndrome
Feb 06, 2019: Rexahn announces presentation on its drug candidate RX-0201 at the 2019 ASCO Genitourinary Cancers Symposium
Nov 16, 2018: ArQule presents clinical and preclinical data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium
Nov 12, 2018: NCI-MATCH precision medicine cancer trial enrolling 7-8 new patients weekly
Nov 08, 2018: ArQule to present clinical and preclinical data for ARQ 751 at the 30th EORTC/AACR/NCI symposium
Oct 19, 2018: ArQule presents orphan disease clinical data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for its pan-AKT inhibitor, Miransertib (ARQ 092)
Oct 04, 2018: ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics 2018 Annual Meeting
Sep 13, 2018: Miransertib (ARQ 092) granted fast track designation for the treatment of PIK3CA-related overgrowth spectrum (PROS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by ArQule Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Bayer AG, H2 2019
Pipeline by Laekna Therapeutics Shanghai Co Ltd, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Merck KGaA, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Rexahn Pharmaceuticals Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Dormant Products, H2 2019 (Contd..3), H2 2019
Dormant Products, H2 2019 (Contd..4), H2 2019
Discontinued Products, H2 2019

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

ArQule Inc
AstraZeneca Plc
Bayer AG
Laekna Therapeutics Shanghai Co Ltd
Merck & Co Inc
Merck KGaA
Novartis AG
Rexahn Pharmaceuticals Inc


More Publications